EUVIMEDEUVIMED entdecken
Crossref

Torasemide Prolonged-Release: A Review of its use in the Management of Edema Associated with Congestive Heart Failure

Clinical Medicine Reviews in Vascular Health · 2010

DOI: 10.4137/cmrvh.s3275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Medicine Reviews in Vascular Health, 2010.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Loop diuretics are currently recommended by scientific societies and associations of cardiology for treatment of symptoms of heart failure. Furosemide, which belongs to this pharmacological group, is the most commonly used in this disease. Torasemide prolonged-release is an equally effective alternative to furosemide for that purpose, although it is thought that, in patients with heart failure, torasemide has cardiac benefits beyond its diuretic effects. This is due to the ability of torasemide to inhibit the enzyme involved in the myocardial extracellular generation of collagen type I molecules (also known as procollagen type I carboxy—terminal proteinase (PCP)), so this drug could reverse myocardial fibrosis and reduce collagen type I synthesis in patients with CHF. Furthermore, torasemide is a very safe drug, as this molecule has mild and transient side effects.

Zitieren

APA

(2010). Torasemide Prolonged-Release: A Review of its use in the Management of Edema Associated with Congestive Heart Failure. Clinical Medicine Reviews in Vascular Health. https://doi.org/10.4137/cmrvh.s3275

Vancouver

Torasemide Prolonged-Release: A Review of its use in the Management of Edema Associated with Congestive Heart Failure. Clinical Medicine Reviews in Vascular Health. 2010. doi:10.4137/cmrvh.s3275

BibTeX
@article{euvimed2010,
  title = {Torasemide Prolonged-Release: A Review of its use in the Management of Edema Associated with Congestive Heart Failure},
  journal = {Clinical Medicine Reviews in Vascular Health},
  year = {2010},
  doi = {10.4137/cmrvh.s3275}
}
Kostenlos starten →